• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Stern Adam K was granted 19,607 shares, increasing direct ownership by 100% to 39,214 units (SEC Form 4)

    11/17/23 6:43:26 PM ET
    $ONVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ONVO alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    STERN ADAM K

    (Last) (First) (Middle)
    11555 SORRENTO VALLEY ROAD, SUITE 100

    (Street)
    SAN DIEGO CA 92121

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    ORGANOVO HOLDINGS, INC. [ ONVO ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    11/17/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 11/17/2023 A 19,607(1) A $0.00 39,214 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The reported securities are represented by restricted stock units, which shall vest on the earlier of November 17, 2024 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control.
    /s/ Keith Murphy, attorney-in-fact 11/17/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ONVO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ONVO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ONVO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market

      SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development. VivoSim will offer liver and intestinal toxicology insights using its premier new approach methodologies (NAM) models, following the announcement of the FDA to phase out animal testing requirements in favor of these non-animal NAM methods. The FDA's push to phase out animal models, announced on April 10, is expected to provide a powerful accelerant to VivoSim's market adoption, disrupting a >$10B animal testing market with models that are more predictive and ethically sound. As FDA Commiss

      4/24/25 8:05:11 AM ET
      $ONVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • VivoSim to Carry Forward Organovo 3D Bioprinting

      SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (the "Company") announced that it will carry forward its 3D bioprinting and legacy technology as VivoSim Labs, Inc. A name change of the Company to VivoSim Labs, Inc. will be effective on April 24, 2025, and the Company's common stock will begin trading on the Nasdaq Capital Market under the new ticker symbol "VIVS" at market open on April 24, 2025. No action is required by existing stockholders with respect to the name and ticker symbol change. The Company's common stock will continue to be listed on the Nasdaq Capital Market and the CUSIP number assigned to the Company's common stock (68620A302) wil

      4/23/25 8:05:21 AM ET
      $ONVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements

      SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today reported preliminary unaudited cash for the fiscal year ending March 31, 2025, and net cash utilization results for the fiscal fourth quarter of 2025. The Company expects to release full fiscal second-quarter financial results the week of June 9-13, 2025. The Company also gave guidance that, as its common stock has been trading above the $1.00 minimum bid price required, it expects to meet the requirements for continued listing on the Nasdaq Capita

      4/2/25 8:05:00 AM ET
      $ONVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ONVO
    SEC Filings

    See more
    • Organovo Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - VivoSim Labs, INC. (0001497253) (Filer)

      4/24/25 8:30:13 AM ET
      $ONVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Organovo Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ORGANOVO HOLDINGS, INC. (0001497253) (Filer)

      4/23/25 8:06:08 AM ET
      $ONVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B5 filed by Organovo Holdings Inc.

      424B5 - ORGANOVO HOLDINGS, INC. (0001497253) (Filer)

      4/11/25 9:16:35 AM ET
      $ONVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ONVO
    Leadership Updates

    Live Leadership Updates

    See more
    • Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

      BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, effective March 11, 2025 (the "Effective Date"). In addition, Matthew Wikler, M.D., and Natasha Giordano stepped down from the Board on the Effective Date. "We are thrilled to announce the addition of Keith and Edward to our Board," stated Jerome D. Jabbour, Chief Executive Officer of Matinas. "Their deep industry experience, leadership expertise, and capital markets acumen will be of great value as we move the company forward into a new era continu

      3/11/25 7:00:00 AM ET
      $GRCE
      $MTNB
      $ONVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Organovo Announces Appointment of Norman Staskey as Chief Financial Officer

      SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announced that it had appointed Norman Staskey as Chief Financial Officer. Mr. Staskey has worked for Danforth Advisors since 2021, working as Chief Financial Officer for clients such as Azitra, Inc., a biotechnology company developing novel dermatology therapeutic technologies. Norm has over 25 years working in capital market and M&A transactions most recently as a Managing Director in EY's (formally Ernst & Young) national transactions practice wh

      1/6/25 8:05:55 AM ET
      $ONVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ONVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Organovo Holdings Inc.

      SC 13G - ORGANOVO HOLDINGS, INC. (0001497253) (Subject)

      11/14/24 3:34:49 PM ET
      $ONVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Organovo Holdings Inc. (Amendment)

      SC 13G/A - ORGANOVO HOLDINGS, INC. (0001497253) (Subject)

      2/12/24 6:17:19 PM ET
      $ONVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Organovo Holdings Inc. (Amendment)

      SC 13G/A - ORGANOVO HOLDINGS, INC. (0001497253) (Subject)

      2/5/24 6:08:57 AM ET
      $ONVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ONVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Staskey Norm

      3 - ORGANOVO HOLDINGS, INC. (0001497253) (Issuer)

      1/8/25 4:05:03 PM ET
      $ONVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Gobel David was granted 19,607 shares, increasing direct ownership by 100% to 39,214 units (SEC Form 4)

      4 - ORGANOVO HOLDINGS, INC. (0001497253) (Issuer)

      8/9/24 4:01:07 PM ET
      $ONVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Milhous Alison Tjosvold was granted 19,607 shares, increasing direct ownership by 50% to 58,821 units (SEC Form 4)

      4 - ORGANOVO HOLDINGS, INC. (0001497253) (Issuer)

      8/9/24 4:01:05 PM ET
      $ONVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care